Evidence map›Paper›PMID 36017672›Full record

ArticleJournal of tissue engineering and regenerative medicine2022

Biomaterials directed activation of a cryostable therapeutic secretome in induced pluripotent stem cell derived mesenchymal stromal cells.

Sara Romanazzo, Chantal Kopecky, Shouyuan Jiang, Riddhesh Doshi, Vipul Mukund, Pallavi Srivastava, Jelena Rnjak-Kovacina, Kilian Kelly, Kristopher A Kilian

Open access · hybridAbstract read
In one paragraph

Article in Journal of tissue engineering and regenerative medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sara RomanazzoSchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-7074-1248
Chantal KopeckySchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.
Shouyuan JiangGraduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia.
Riddhesh DoshiSchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.
Vipul MukundSchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.
Pallavi SrivastavaSchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.
Jelena Rnjak-KovacinaGraduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia.
Kilian KellyCynata Therapeutics Limited, Cremorne, Victoria, Australia.
Kristopher A KilianSchool of Chemistry, Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-8963-9796
UNSW Sydney · AUIo Therapeutics (United States) · US

Funding

Wellcome Trust 101896
6 · The paper itself

Abstract

Mesenchymal stem cell therapy has suffered from wide variability in clinical efficacy, largely due to heterogeneous starting cell populations and large-scale cell death during and after implantation. Optimizing the manufacturing process has led to reproducible cell populations that can be cryopreserved for clinical applications. Nevertheless, ensuring a reproducible cell state that persists after cryopreservation remains a significant challenge, and is necessary to ensure reproducible clinical outcomes. Here we demonstrate how matrix-conjugated hydrogel cell culture materials can normalize a population of induced pluripotent stem cell derived mesenchymal stem cells (iPSC-MSCs) to display a defined secretory profile that promotes enhanced neovascularization in vitro and in vivo. Using a protein-conjugated biomaterials screen we identified two conditions-1 kPa collagen and 10 kPa fibronectin coated polyacrylamide gels-that promote reproducible secretion of pro-angiogenic and immunomodulatory cytokines from iPSC-MSCs that enhance tubulogenesis of endothelial cells in Geltrex and neovascularization in chick chorioallantoic membranes. Using defined culture substrates alone, we demonstrate maintenance of secretory activity after cryopreservation for the first time. This advance provides a simple and scalable approach for cell engineering and subsequent manufacturing, toward normalizing and priming a desired cell activity for clinical regenerative medicine.

Indexed as

Induced Pluripotent Stem CellsMesenchymal Stem CellsBiocompatible MaterialsCell DifferentiationEndothelial CellsSecretomeBiocompatible MaterialscryopreservationcytokinesiPSC-MSCsstem cell therapytubulogenesis

Identifiers

PMID36017672
PMCPMC9804847
OpenAlexW4293200081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.